Matt Niederst, Ph.D.

Dr. Matt Niederst brings a breadth of experience in cancer cell biology, therapeutic resistance and multiple aspects of oncology drug discovery to his role as head of Biology at Delphia. Prior to Delphia, Matt worked at Novartis on several projects in target identification, drug discovery and translational research. Most recently, he led multiple programs from project initiation to development candidate nomination, with three molecules currently under clinical investigation.    

Matt received his B.S. in Biology from Allegheny College, a Ph.D. in Biomedical Sciences from UCSD, and his post-doctoral training at the Mass General Cancer Center.